Please login to the form below

Not currently logged in
Email:
Password:

Dacogen

This page shows the latest Dacogen news and features for those working in and with pharma, biotech and healthcare.

Otsuka to buy cancer biopharma Astex

Otsuka to buy cancer biopharma Astex

Otsuka to buy cancer biopharma Astex. Takes control of company behind Dacogen in $886m deal. ... Astex' lead product is Dacogen (decitabine), which is approved for the treatment of myelodysplastic syndromes and for acute myeloid leukaemia (AML) in

Latest news

  • European approvals for J&J cancer treatments

    European approvals for J&J cancer treatments. EC passes new Dacogen indications and backs subcutaneous Velcade. ... The European Commission has approved an extra indication for Johnson &Johnson's cancer drug Dacogen as well as a subcutaneous version of

  • Developing drugs to conquer cancer Developing drugs to conquer cancer

    Eisai reported new results on eribulin (Halaven) in early-stage breast cancer and decitabine (Dacogen) in acute myeloid leukemia, as well as new data on several phase I agents under investigation

  • Cancer data presented at ASCO

    Elsewhere, Eisai presented data concerning a phase III study of DNA methylation inhibitor Dacogen (decitabine) for injection in acute myeloid leukaemia (AML).

  • J&J positive about pipeline

    this month; and Dacogen (decitabine), currently sold as a treatment for myelodysplastic syndromes, for the new indication of acute myeloid leukaemia.

  • SuperGen and Astex to merge

    It plans to leverage a revenue stream from its product Dacogen, marketed in North America by Eisai and in the rest of the world by Johnson &Johnson.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2013 Pharma deals during September 2013

    Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics